Zanetta Bryant
Primary Care · Newnan, GANPI 1114332657
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 517 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 56 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,165 and has fallen 82.4% since, to $557 in 2025. Among primary care clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 517 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- UCB, Inc.$870
- SK Life Science, Inc.$576
- Novartis$565
- MDD US Operations, LLC$524
- Neurocrine Biosciences, Inc.$460
- plus $6K from 50 others
What the payments were for
- Food & beverage$10,61399%
- Education$761%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,690 in reported general payments places this provider in the 95th percentile of 235 primary care providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 52 | $43,443 |
| UbrelvyUbrogepant | 16 | $24,932 |
| Aimovig AutoinjectorErenumab-Aooe | 29 | $21,463 |
| NeuproRotigotine | 19 | $19,100 |
| RytaryCarbidopa/Levodopa | 18 | $11,366 |
| Memantine Hcl | 252 | $6,674 |
| Rivastigmine | 19 | $2,913 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 58 | $2,627 |
| Gabapentin | 97 | $2,055 |
| Primidone | 27 | $1,890 |
| Levetiracetam | 38 | $1,402 |
| Divalproex Sodium | 83 | $1,308 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 15 | $1,083 |
| RivastigmineRivastigmine Tartrate | 46 | $886 |
| Donepezil Hcl | 111 | $848 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy | $1,314 | $24,93216 claims |
| UCB, Inc.Neupro | $870 | $19,10019 claims |
| Amneal Pharmaceuticals LLCRytary | $246 | $11,36618 claims |
| Upsher-smith Laboratories LLCTopiramate | $98 | $34120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 235 primary care providers in Georgia.
Other primary care in Newnan
- Pamela TurkDouglas$15K
- Morgan JonesLawrenceville$14K
- Jessi HaleColumbus$13K
- Meredith CarrAugusta$12K
- Ashtyn ZaryckiSavannah$12K
- Hannah CummingsSuwanee$9K
- Michelle LadewigGainesville$7K
- Lucia OcanoviciuCanton$7K
- Sarah NewGrovetown$7K
- Erin EverettAtlanta$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.